Huntington's News

HD Service at Westmead approved to participate in 2 new drug trials

Posted: 13th May 2019

The Huntington Disease Service at Westmead Hospital has been approved to participate in two new drug trials, called PRECISION-HD1 and PRECISION-HD2. Each study tests a separate Huntingtin-lowering (also known as gene silencing) agent. They are run by a company called Wave Life Sciences based in Massachusetts, USA. The studies involve lumbar punctures, MRI scans, assessments and questionnaires.

These are Phase 1b/2a trials, meaning that they are testing an experimental treatment in humans for the first time. The main goal is to assess whether the treatments are safe and well tolerated in the treatment of Huntington’s disease when compared with a placebo control. Participants must be between the ages of 25-65, have early stage Huntington’s disease, and meet additional criteria.

The study has already commenced overseas. Information can be found at https://clinicaltrials.gov/ct2/show/NCT03225833?recrs=a&cond=huntington%27s+disease&draw=2&rank=16 and https://clinicaltrials.gov/ct2/show/NCT03225846?recrs=a&cond=huntington%27s+disease&draw=2&rank=15. It is expected that together the two studies will involve approximately 96 people worldwide.

If you would like more information, you can call the Huntington Disease Service at Westmead on 0456 740 612. The phone will be monitored on Mondays and Thursdays. Please leave a message if we do not answer when you call.

Huntington’s NSW & ACT and the Huntington Disease Service at Westmead will continue to provide updates on HD research through the Huntington’s NSW & ACT website and Facebook page

Walk 4 Hope 2019 - Earlybird Registrations Open Now

Posted: 29th April 2019

Orange           Saturday 31 August
Canberra        Sunday 8 September
Speers Point  Saturday 14 September
Parramatta     Sunday 22 September

Election commitments sought from federal politicians

Posted: 16th April 2019

Huntington’s associations have been working in partnership with other neurological organisations in developing this document seeking election commitments for our members.

Please feel free to use it if you run across anyone running for election on 18 May.

Download NAA Election commitments.pdf (2.17 MB)

Establishment of an Ageing and Disability Commissioner

Posted: 5th March 2019

The NSW Government will establish an Ageing and Disability Commissioner from 1 July 2019, to better protect adults with disability and older people from abuse, neglect and exploitation in home and community settings.

Find out more or download the factsheet.

Vignettes needed for new edition of HD facts

Posted: 5th February 2019

Dr Oliver Quarrell is compiling the 3rd edition of HD facts. This book is designed to give information to families and carers and is published by Oxford University Press. 

Are you able to write up to 500 words on one of these topics to be included as a perspective or experience of a patient, carer, or someone at risk? There will not be a payment for the entry but your contribution can be acknowledged if you wish.

  • Behavioural and emotional aspects of HD
  • Juvenile HD
  • Predictive testing
  • Testing in pregnancy
  • Participating in clinical trials

Please send your  up to 500 words to HD.thefacts@nhs.net

Dr Quarrell cannot guarantee that every entry will be used but the idea is to publish a perspective from families as part of the book. If a lot of entries are received then Dr Quarrell will write to you and ask if they can be published separately on a website.

Thank you for your contribution.

NEW EXECUTIVE OFFICER ANNOUNCED

Posted: 21st December 2018

The Board of Huntington’s NSW ACT is very pleased to announce the appointment of Lewis Kaplan as Executive Officer to lead our team from 4 February 2019.

Lewis is replacing our long-term Executive Officer, Robyn Kapp, who is retiring.

Lewis brings a wealth of experience across the public and primary health sector. Over 35 years, his previous roles have included national CEO of Diabetes Australia, Executive Director of Australian Red Cross NSW, CEO of Alzheimer’s Australia NSW and Executive Director of Council on the Ageing NSW.

The Board warmly welcomes Lewis and looks forward to working with him as we serve the Huntington’s community across NSW and ACT.

Brian Rumbold, Chairman 

 

ROCHE ANNOUNCES DETAILS OF ITS 'PIVOTAL' HUNTINGTIN-LOWERING STUDY

Posted: 19th September 2018

It’s a time of huge developments in the field of huntingtin-lowering drugs, which aim to reduce production of the huntingtin protein that causes Huntington’s disease. At the European Huntington’s Disease Network (EHDN) meeting this past week, Roche announced firm details of the first ever pivotal study of a huntingtin lowering drug – RG6042, which you might know better as Ionis-HTTRx. So what do we know about the trial? Read more here https://en.hdbuzz.net/263

INSURANCE & GENETIC INFORMATION

Posted: 1st August 2018

Use of Genetic Information in Insurance Underwriting

You are invited to participate in a short 15 to 20-minute anonymous online survey about your experiences and attitudes concerning use of genetic information in health, life and travel insurance in Australia.

You can participate if you are aged 18 years or over, have a family history of a genetic condition, and were asymptomatic at the time of your experience.

If you are interested in participating, please go to: https://www.surveymonkey.com/r/insurance18 Here, you will be provided with a participant information sheet with details about the research study. For further questions, please contact the student researcher, Brenely Vargas Murillo at nvar6478@uni.sydney.edu.au.

UPDATE FROM WESTMEAD HD SERVICE & HNSW&ACT

Posted: 3rd January 2018

On Monday, 11th December, 2017 Huntington’s disease was back in the international spotlight – the last time the disease hit the headlines was when the gene was discovered in 1993. Social media has been buzzing with news of a research breakthrough. A study showed that a drug, Ionis-HTTRx, could lower the amount of the mutant protein “huntingtin” (mHTT) in individuals with early stage HD. This is important because toxic mHTT is believed to be part of the mechanism leading to HD symptoms. 

When testing new drugs, the very first thing we need to know is that they are safe - and this study found no evidence that patients experienced unpleasant or dangerous side-effects or other adverse events.

There is no doubt that this is extremely exciting news. This first study of Ionis-HTTRx, which began in July, 2015, had 46 participants, recruited from 9 centres in Great Britain, Canada and Germany. The trial was not designed to address the question of whether the drug has an effect on the onset or the course of the disease, and a further, larger trial will be needed to demonstrate this.

The press release issued by the company which ran the study, Ionis Pharmaceuticals, reported that the next phase of research will be handled by the pharmaceutical company Roche. The only information provided by Roche about the next stage of research is that “future studies for the program will be conducted globally” and “information will be provided as soon as possible.”

Like others around the world, we are eagerly awaiting announcements about the next stage of the study. Until then, there is nowhere in Australia, or anywhere else in the world, where one can join an Ionis-HTTRx study.

The Westmead HD Service and Huntington’s NSW & ACT work extremely closely together. We will ensure that any news about new trials will be distributed immediately through the Association’s website, Facebook page or directly through emails (if you are a member or client of the Association).

Watch this space!


Dr Clement Loy                    Robyn Kapp OAM
Director & Neurologist          Executive Officer
HD Service                           HNSW & ACT

Westmead Hospital              www.huntingtonsnsw.org.au                                                                                                      

For a good, reliable source of information about this study, including an informative Q&A about the research and most HD research results, we suggest you look at the HD-Buzz website:  https://en.hdbuzz.net

If you or anyone you know have any concerns about HD, you can make an appointment to attend the Westmead Hospital HD clinic. To discuss what a clinic visit involves, you can ring the Outreach Team 8890 9960, or to make an appointment ring 8890 6544.

If you are interested in participating in research, you may also want to consider the global Enroll-HD study (https://www.enroll-hd.org) This is an observational study (no drug treatment) for HD families. You can find out more about Enroll-HD by contacting the researchers at Westmead Hospital, on 8890 6310 or 0438 604 719 (Mondays and Thursdays).

 

BIGGEST BREAKTHROUGH SINCE THE DISCOVERY OF THE HD GENE IN 1993

Posted: 12th December 2017

In an announcement likely to stand as one of the biggest breakthroughs in Huntington's disease since the discovery of the HD gene in 1993, Ionis and Roche have announced that the first human trial of a huntingtin-lowering drug, IONIS-HTTRx, demonstartes that it reduces mutant huntingtin in the nervous system, and is safe and well-tolerated. More information can be found at HDBuzz

 

Pages

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.